LitCoin-sentences  

PubMed:18779591 JSONTXT 27 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 0-107 Sentence denotes Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
T2 108-211 Sentence denotes There is currently no known genetic disease linked to prolactin (Prl) or its receptor (PrlR) in humans.
T3 212-422 Sentence denotes Given the essential role of this hormonal system in breast physiology, we reasoned that genetic anomalies of Prl/PrlR genes may be related to the occurrence of breast diseases with high proliferative potential.
T4 423-609 Sentence denotes Multiple fibroadenomas (MFA) are benign breast tumors which appear most frequently in young women, including at puberty, when Prl has well-recognized proliferative actions on the breast.
T5 610-862 Sentence denotes In a prospective study involving 74 MFA patients and 170 control subjects, we identified four patients harboring a heterozygous single nucleotide polymorphism in exon 6 of the PrlR gene, encoding Ile(146)-->Leu substitution in its extracellular domain.
T6 863-1323 Sentence denotes This sole substitution was sufficient to confer constitutive activity to the receptor variant (PrlR(I146L)), as assessed in three reconstituted cell models (Ba/F3, HEK293 and MCF-7 cells) by Prl-independent (i) PrlR tyrosine phosphorylation, (ii) activation of signal transducer and activator of transcription 5 (STAT5) signaling, (iii) transcriptional activity toward a Prl-responsive reporter gene, and (iv) cell proliferation and protection from cell death.
T7 1324-1440 Sentence denotes Constitutive activity of PrlR(I146L) in the breast sample from a patient was supported by increased STAT5 signaling.
T8 1441-1539 Sentence denotes This is a unique description of a functional mutation of the PrlR associated with a human disease.
T9 1540-1753 Sentence denotes Hallmarks of constitutive activity were all reversed by a specific PrlR antagonist, which opens potential therapeutic approaches for MFA, or any other disease that could be associated with this mutation in future.